Contact
 
News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

International Centre for Infectious Diseases (ICID) to House CHVI R&D Alliance Coordinating Office - December 1, 2011

 

The Canadian HIV Vaccine Initiative (CHVI) announced that the International Centre for Infectious Diseases (ICID) will house the new Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO). The ACO will provide support, establish networks, offer leadership in innovation to accelerate efforts to develop a vaccine.  The full announcement is located here (http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2011/2011_161-eng.php).

 

Correlates of Protection and HIV Vaccine Development - October 28, 2011

The Lancet published a piece on correlates of protection and HIV vaccine development in its November issue.  Click below to read the article.

AIDS Vaccine 2011 to Open in Bangkok - September 7, 2011

In the midst of the most promising era in HIV prevention research since the AIDS epidemic began, scientists from around the world will present more than 400 new studies outlining advances in the search for a safe and effective HIV vaccine at AIDS Vaccine 2011.  This global conference, the world’s only scientific meeting dedicated exclusively to HIV vaccine research, runs Monday, 12 September through Thursday, 15 September in Bangkok.  This is the first time that the annual AIDS Vaccine conference has been held in Asia.

AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV Discovery provides new directions for AIDS vaccine design - August 17, 2011

IAVI, The Scripps Research Institute, Theraclone Sciences and Monogram Biosciences (a LabCorp company), published in the journal, Nature, today the discovery of 17 new broadly neutralizing antibodies against HIV. Together these discoveries with other recent discoveries in the neutralizing antibody arena represent tremendous progress in this area of AIDS vaccine research.  The IAVI announcement is available below.

Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs - July 19, 2011

The HIV Vaccines and Microbicides Resource Tracking Working Group released its seventh report on HIV prevention research funding, which states that new investment is critical to capitalizing on HIV prevention breakthroughs. The full report is available here: http://www.hivresourcetracking.org/sites/default/files/RTWG-Capitalizing%20on%20Scientific%20Progress.pdf

AVAC Statement on Results of New PrEP Trials - July 13, 2011

AVAC says results of new PrEP trials provide clear evidence that antiretroviral  drugs for prevention can help end the AIDS epidemic; calls for quick action  to move landmark HIV prevention results toward lifesaving programs.  Read the full statement below. 

IAVI Announces the Appointment of New President & CEO - July 7, 2011

IAVI today announced the appointment of Margaret (Margie) McGlynn as President and Chief Executive Officer. McGlynn, replaces Seth Berkley, IAVI’s Founding President and CEO.  The full announcement is below.

Request for Applications: Workshop on Statistical Methods in HIV Vaccine Trial Design and Evaluation - June 10, 2011

New Enterprise-OCTAVE Workshop for Young and Early Career Investigators

Statistical Methods in HIV Vaccine Trial Design and Evaluation

11-12 September 2011 Bangkok, Thailand (prior to AIDS Vaccine 2011)

Dr. Alan Bernstein Stepping Down As Executive Director of the Global HIV Vaccine Enterprise - June 8, 2011

The Board of Directors of the Global HIV Vaccine Enterprise today announced that Alan Bernstein, Ph.D. will step down after three and a half years as the inaugural executive director of the Enterprise Secretariat at the end of June 2011.   The full announcement is below.

Dr. Anthony Fauci Reflects on 30 Years of HIV/AIDS - May 27, 2011

To commemorate the 30th anniversary of the first reported cases of what is now known as AIDS, Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, describes his personal experiences as a physician, leading HIV/AIDS researcher, and scientific administrator during a special lecture and editorial in the Washington Post.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account